{"id":454193,"date":"2021-03-09T16:15:47","date_gmt":"2021-03-09T21:15:47","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454193"},"modified":"2021-03-09T16:15:47","modified_gmt":"2021-03-09T21:15:47","slug":"marker-therapeutics-reports-fiscal-year-2020-operating-and-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-reports-fiscal-year-2020-operating-and-financial-results\/","title":{"rendered":"Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results"},"content":{"rendered":"
\n

– Dosed first patient in the Company’s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia –<\/h2>\n

– Completed construction of new in-house cGMP manufacturing facility in Houston to supply MultiTAA-specific T cell products, including MT-401, for clinical activities and potential commercialization; facility expected to be fully operational in 1H 2021 –<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n

\n HOUSTON<\/span>, March 9, 2021<\/span> \/PRNewswire\/ —\u00a0Marker Therapeutics, Inc.\u00a0(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2020<\/span>. \u00a0<\/p>\n

\n

\n
\n \"Marker
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We are proud of our Company’s continued progress, which has positioned us for a busy and productive year ahead,” said Peter L. Hoang<\/span>, President & CEO of Marker Therapeutics. “Recently, we dosed the first patient in the safety lead-in portion of our Phase 2 trial in post-transplant acute myeloid leukemia (AML). In the fourth quarter, we completed construction of a new in-house cGMP manufacturing facility in Houston<\/span>, which we anticipate will be fully operational in the first half of this year. We also continue to optimize the MT-401 cell therapy manufacturing process, which we believe could result in an increase in the number of T cells available for patient administration, superior T cell phenotype and antigen specificity, and the potential for improved patient outcomes.” <\/p>\n

\n RECENT PROGRAM UPDATES <\/b>\n <\/p>\n

\n
\n MT-401: Multi-Antigen Targeted (MultiTAA)-Specific T Cell Product Candidate for AML<\/u>
\n <\/b>\n <\/p>\n

\n Phase 2 AML Trial <\/b>\n <\/p>\n